ACELYRIN, Inc. (Nasdaq: SLRN) was a late-stage clinical biopharmaceutical company headquartered in Agoura Hills, California, focused on accelerating the development and commercialization of medicines in immunology. Its lead candidates were izokibep, an anti-IL-17A small protein therapeutic, and lonigutamab, a humanized IgG1 monoclonal antibody against IGF-1R. It completed a $540M IPO in May 2023, and on May 21, 2025 it merged with a subsidiary of Alumis, Inc. and survives as a wholly owned Alumis subsidiary. Its corporate domain acelyrin.com now 301-redirects to alumis.com. The company is a drug developer, not a software vendor: it published no developer program, public API, SDK, webhook surface, or machine-readable specification, and no GitHub organization exists under the ACELYRIN name.
ACELYRIN is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Pharmaceuticals, and Immunology.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/acelyrin: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: acelyrin
name: ACELYRIN
description: 'ACELYRIN, Inc. (Nasdaq: SLRN) was a late-stage clinical biopharmaceutical company headquartered in Agoura Hills,
California, focused on accelerating the development and commercialization of medicines in immunology. Its lead candidates
were izokibep, an anti-IL-17A small protein therapeutic, and lonigutamab, a humanized IgG1 monoclonal antibody against IGF-1R.
It completed a $540M IPO in May 2023, and on May 21, 2025 it merged with a subsidiary of Alumis, Inc. and survives as a
wholly owned Alumis subsidiary. Its corporate domain acelyrin.com now 301-redirects to alumis.com. The company is a drug
developer, not a software vendor: it published no developer program, public API, SDK, webhook surface, or machine-readable
specification, and no GitHub organization exists under the ACELYRIN name.'
url: https://raw.githubusercontent.com/api-evangelist/acelyrin/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
x-parent-company: alumis
x-secondary-market-listing: https://forgeglobal.com/acelyrin_stock/
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Pharmaceuticals
- Immunology
- Clinical Trials
- Healthcare
- Acquired
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/acelyrin-domain-security.yml
- type: Website
url: https://acelyrin.com/
x-enrichment:
date: '2026-09-06'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: defunct
detail: ACELYRIN was absorbed into Alumis, Inc. on 2025-05-21 as a wholly owned subsidiary and its corporate domain acelyrin.com
now 301-redirects to www.alumis.com, so the only surviving surface belongs to the acquirer; the company was a clinical-stage
drug developer that never published a developer portal, API, or GitHub organization.
evidence:
- url: https://acelyrin.com/
status: 301
- url: https://www.alumis.com/
status: 200
- url: https://acelyrin.com/.well-known/api-catalog
status: 404
- url: https://acelyrin.com/openapi.json
status: 404
- url: https://api.github.com/orgs/acelyrin
status: 404
checked: '2026-09-06'
x-legal-name: ACELYRIN, Inc.
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →